The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
In the latest session, Myriad Genetics, Inc (NASDAQ: MYGN) closed at $6.14 down -0.16% from its previous closing price of $6.15. In other words, the price has decreased by -$0.16 from its previous closing price. On the day, 0.71 million shares were traded. MYGN stock price reached its highest trading level at $6.305 during the session, while it also had its lowest trading level at $6.1.
Ratios:
For a deeper understanding of Myriad Genetics, Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.12 and its Current Ratio is at 2.33. In the meantime, Its Debt-to-Equity ratio is 0.57 whereas as Long-Term Debt/Eq ratio is at 0.55.
Wells Fargo Downgraded its Overweight to Equal Weight on May 07, 2025, while the target price for the stock was maintained at $6.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MYGN now has a Market Capitalization of 572332224 and an Enterprise Value of 639232256. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.69 while its Price-to-Book (P/B) ratio in mrq is 1.53. Its current Enterprise Value per Revenue stands at 0.775 whereas that against EBITDA is -24.398.
Stock Price History:
The Beta on a monthly basis for MYGN is 1.81, which has changed by -0.55442667 over the last 52 weeks, in comparison to a change of 0.14778805 over the same period for the S&P500. Over the past 52 weeks, MYGN has reached a high of $15.47, while it has fallen to a 52-week low of $3.76. The 50-Day Moving Average of the stock is -13.00%, while the 200-Day Moving Average is calculated to be -5.69%.
Shares Statistics:
For the past three months, MYGN has traded an average of 1.06M shares per day and 944050 over the past ten days. A total of 93.10M shares are outstanding, with a floating share count of 88.73M. Insiders hold about 4.81% of the company’s shares, while institutions hold 97.84% stake in the company. Shares short for MYGN as of 1765756800 were 8629605 with a Short Ratio of 8.18, compared to 1763078400 on 7694493. Therefore, it implies a Short% of Shares Outstanding of 8629605 and a Short% of Float of 13.01.
Earnings Estimates
Current recommendations for the stock of the company come from 12.0 analysts. The consensus estimate for the next quarter is -$0.0, with high estimates of $0.02 and low estimates of -$0.04.
Analysts are recommending an EPS of between $0.02 and -$0.01 for the fiscal current year, implying an average EPS of $0.01. EPS for the following year is $0.07, with 12.0 analysts recommending between $0.19 and -$0.03.
Revenue Estimates
A total of 12 analysts believe the company’s revenue will be $206.91M this quarter.It ranges from a high estimate of $208.57M to a low estimate of $204.68M. As of. The current estimate, Myriad Genetics, Inc’s year-ago sales were $210.6MFor the next quarter, 12 analysts are estimating revenue of $210.47M. There is a high estimate of $215.27M for the next quarter, whereas the lowest estimate is $206M.
A total of 12 analysts have provided revenue estimates for MYGN’s current fiscal year. The highest revenue estimate was $823.27M, while the lowest revenue estimate was $819.38M, resulting in an average revenue estimate of $821.55M. In the same quarter a year ago, actual revenue was $837.6MBased on 12 analysts’ estimates, the company’s revenue will be $867.44M in the next fiscal year. The high estimate is $896.3M and the low estimate is $846M.
